Death due to consumption of ibogaine: case report

Acimovic, T.; Atanasijević, Tatjana; Denić, Kristina; Lukić, Vera; Popović, Vladimir; Bogdanović, Milenko

doi:10.1007/s12024-020-00342-0

Cited by 10 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ibogaine can decrease HR and cause life-threatening cardiac arrhythmias ( Koenig et al, 2014 ) that have to be controlled during treatment. The use of ibogaine has also led to several reported cases of sudden death with an unclear cause ( Maas and Strubelt, 2006 ; Alper et al, 2012 ; Aćimović et al, 2021 ). This may be related to a blockage of human ERG potassium channels in the heart and further abrupt prolongation of QT interval on electrocardiogram associated with ventricular tachyarrhythmias ( Koenig et al, 2014 ).…”

Section: Ibogainementioning

confidence: 99%

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

Vorobyeva¹,

Kozlova

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Classical psychedelics represent a family of psychoactive substances with structural similarities to serotonin and affinity for serotonin receptors. A growing number of studies have found that psychedelics can be effective in treating various psychiatric conditions, including post-traumatic stress disorder, major depressive disorder, anxiety, and substance use disorders. Mental health disorders are extremely prevalent in the general population constituting a major problem for the public health. There are a wide variety of interventions for mental health disorders, including pharmacological therapies and psychotherapies, however, treatment resistance still remains a particular challenge in this field, and relapse rates are also quite high. In recent years, psychedelics have become one of the promising new tools for the treatment of mental health disorders. In this review, we will discuss the three classic serotonergic naturally occurring psychedelics, psilocybin, ibogaine, and N, N-dimethyltryptamine, focusing on their pharmacological properties and clinical potential. The purpose of this article is to provide a focused review of the most relevant research into the therapeutic potential of these substances and their possible integration as alternative or adjuvant options to existing pharmacological and psychological therapies.

show abstract

Section: Ibogainementioning

confidence: 99%

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

Vorobyeva¹,

Kozlova

2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…6,43 Hypothetically, recent publications state that severe episodes are usually associated with the administration of high doses. 2,38,47 However, the lack of a safe variant of the substance and the absence of technical-scienti c publications to support its commercialization as a drug continue to be an impediment to its clinical use. 43 On the other hand, publication 1 points to the possibility of safe doses, an argument that has gathered scienti c support and was published in Nature (very high impact factor = 49.962 (https://www.nature.com/nature/journal-impact)), whose co-authors have ties to USA institutions.…”

Section: Organizationsmentioning

confidence: 99%

Three-decade research development of ibogaine use for the treatment of substance-related disorders: a bibliometric analysis

Fernandes-Nascimento

Negrão

Viana-Ferreira

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective To evaluate the publications on ibogaine use for substance-related disorders treatment over the last three decades. Method Bibliometric analysis of publications on ibogaine for the treatment of substance-related disorders from 1991 to 2020 using VOSviewer software. We performed a Scopus database search using the terms: ibogaine, 12-methoxybogamine, endabuse, tabernanthe iboga, NIH-10567, and noribogaine. Publications related to ibogaine was compared between the three decades using the Tukey test at 95% confidence level, and the behavior period evaluated considered linear and polynomial regression models. Results Regression models indicated that publications dedicated to ibogaine for treating substance use disorders grew by 5.1 publications per year between 1991–2000 (R2 = 0.993). The period from 2001 to 2020 showed a different expansion compared to the previous period, with fluctuations within a constant flow of publications and an increase in the volume of publications was observed until the middle of this decade (R2 = 0.889). The same tendency was seen in the last decade, 2011–2020 (R2 = 0.949). The US is the most prominent country. Conclusion The present study indicates that, despite differences and fluctuations among the decades analyzed, publications continue year by year and propose future directions for new interventions in the public health.

show abstract

“…A total of 33 ibogaine-related deaths have been publicly reported to date. Thirty-two cases (33 including a doublecounted case [12]) have been summarized in a review article by Corkery [13]; one additional case has been published more recently [14]. The deaths occurred between 1990 and 2020.…”

Section: Safetymentioning

confidence: 99%

“…The recent report from Aćimović et al illustrates the difficulties when assessing the causality of ibogaine fatalities based on incomplete information from forensic and toxicologic investigations [14]. The patient, a 27-year-old male heroin addict, was found dead in a rented apartment, where he had spent 3 days with a 'therapist' to undergo an 'addiction treatment.'…”

Section: Safetymentioning

confidence: 99%

Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse

Luz

Mash

2021

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Death due to consumption of ibogaine: case report

Cited by 10 publications

References 5 publications

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

Three-decade research development of ibogaine use for the treatment of substance-related disorders: a bibliometric analysis

Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse

Contact Info

Product

Resources

About